Abingdon has reported FY21 prelims in line with the position outlined at the trading update in April, with revenues of £11.6m, an adj EBITDA loss of £3.3m and cash of £5.0m after significant investment in manufacturing capacity. The pipeline of contract manufacturing opportunities continues to grow, with a number of projects at the final stages of tech transfer, underpinned by initial advance purchase orders for manufacturing batches. Whilst payment for the debt owed by the DHSC has still not ye ....

18 Nov 2021
In line prelims, light at the end of the tunnel

Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
In line prelims, light at the end of the tunnel
Abingdon Health PLC (ABDX:LON) | 6.1 0 0.0% | Mkt Cap: 11.8m
- Published:
18 Nov 2021 -
Author:
Chris Glasper -
Pages:
3 -
Abingdon has reported FY21 prelims in line with the position outlined at the trading update in April, with revenues of £11.6m, an adj EBITDA loss of £3.3m and cash of £5.0m after significant investment in manufacturing capacity. The pipeline of contract manufacturing opportunities continues to grow, with a number of projects at the final stages of tech transfer, underpinned by initial advance purchase orders for manufacturing batches. Whilst payment for the debt owed by the DHSC has still not ye ....